{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:51:05Z","timestamp":1791373865819,"version":"4.3.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","award":["Malaria research Unit, UMR 5246"],"award-info":[{"award-number":["Malaria research Unit, UMR 5246"]}],"id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","award":["Malaria research Unit, UMR 5246"],"award-info":[{"award-number":["Malaria research Unit, UMR 5246"]}],"id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","award":["Malaria research Unit, UMR 246"],"award-info":[{"award-number":["Malaria research Unit, UMR 246"]}],"id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","award":["Malaria research Unit, UMR 5246"],"award-info":[{"award-number":["Malaria research Unit, UMR 5246"]}],"id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","award":["Malaria research Unit, UMR 5246"],"award-info":[{"award-number":["Malaria research Unit, UMR 5246"]}],"id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220211"],"award-info":[{"award-number":["220211"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eunovis","award":["BPI France"],"award-info":[{"award-number":["BPI France"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malaria is responsible for more than half a million deaths each year. Parenteral artesunate is the recommended first-line treatment for severe malaria, but prompt treatment is often delayed affecting patient outcomes. Rectal artesunate is recommended as a pre-referral treatment but shows variable absorption and can be problematic when treating children with gastrointestinal disturbances. Nasal drug administration offers a non-invasive and user-friendly alternative that enables rapid drug absorption. A Phase I, first in human trial was conducted to evaluate the safety, tolerability and pharmacokinetic properties of increasing doses of a novel intranasal formulation of artesunate powder. Three dosing regimens were assessed in adult volunteers. Plasma samples were collected for up to 24\u00a0h post-dose for drug measurements of artesunate and dihydroartemisinin. Intranasal artesunate was safe and well tolerated. Only mild adverse events were reported shortly after drug administration. No severe adverse events were observed. Pharmacokinetic analysis confirmed rapid systemic absorption of artesunate but with high inter-individual variability. Dose-normalized exposures to dihydroartemisinin suggested a non-linear dose-exposure relationship. Further evaluation of this novel formulation of artesunate is needed to establish safety and efficacy in patients with malaria. This, first in human, phase 1 provides justification for subsequent phase 2 clinical trials.<\/jats:p>","DOI":"10.1038\/s41598-026-56855-1","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:34:27Z","timestamp":1783326867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, tolerability and pharmacokinetic properties of intranasal artesunate in a first in human phase 1 trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Karim","family":"Traore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drissa","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye Kassoum","family":"Kone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amatigue","family":"Zeguime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Bengaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Cisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamadou Ali","family":"Thera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Picot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"56855_CR1","unstructured":"World malaria report. (2025). https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2025"},{"key":"56855_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12936-022-04301-8","volume":"21","author":"NJ White","year":"2022","unstructured":"White, N. J. Severe malaria. Malar. J. 21, 284 (2022).","journal-title":"Malar. J."},{"key":"56855_CR3","doi-asserted-by":"crossref","unstructured":"Daily, J. P. & Parikh, S. Malaria. N. Engl. J. Med. 392, 1320\u20131333 (2025).","DOI":"10.1056\/NEJMra2405313"},{"key":"56855_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12916-014-0263-6","volume":"13","author":"K Maitland","year":"2015","unstructured":"Maitland, K. Management of severe paediatric malaria in resource-limited settings. BMC Med. 13, 42 (2015).","journal-title":"BMC Med."},{"key":"56855_CR5","unstructured":"WHO Best Practices for Injections and Related Procedures Toolkit. (World Health Organization, 2010)."},{"key":"56855_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(08)61734-1","volume":"373","author":"MF Gomes","year":"2009","unstructured":"Gomes, M. F. et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 373, 557\u2013566 (2009).","journal-title":"Lancet"},{"key":"56855_CR7","unstructured":"World malaria report. (2022). https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2022"},{"key":"56855_CR8","doi-asserted-by":"publisher","first-page":"e02223","DOI":"10.1128\/AAC.02223-20","volume":"65","author":"C Fanello","year":"2021","unstructured":"Fanello, C. et al. Pharmacokinetic study of rectal artesunate in children with severe malaria in Africa. Antimicrob. Agents Chemother. 65, e02223\u2013e02220 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56855_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris, C. A. et al. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar. J. 10, 263 (2011).","journal-title":"Malar. J."},{"key":"56855_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.4269\/ajtmh.20-0622","volume":"104","author":"D Coulibaly","year":"2021","unstructured":"Coulibaly, D. et al. A decline and age shift in malaria incidence in rural mali following implementation of seasonal malaria chemoprevention and indoor residual spraying. Am. J. Trop. Med. Hyg. 104, 1342\u20131347 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"56855_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12936-015-0805-1","volume":"14","author":"P Pemberton-Ross","year":"2015","unstructured":"Pemberton-Ross, P., Smith, T. A., Hodel, E. M., Kay, K. & Penny, M. A. Age-shifting in malaria incidence as a result of induced immunological deficit: a simulation study. Malar. J. 14, 287 (2015).","journal-title":"Malar. J."},{"key":"56855_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12916-021-02033-1","volume":"19","author":"AL Conroy","year":"2021","unstructured":"Conroy, A. L. et al. Parenteral artemisinins are associated with reduced mortality and neurologic deficits and improved long-term behavioral outcomes in children with severe malaria. BMC Med. 19, 168 (2021).","journal-title":"BMC Med."},{"key":"56855_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","volume":"134","author":"S Grassin-Delyle","year":"2012","unstructured":"Grassin-Delyle, S. et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol. Ther. 134, 366\u2013379 (2012).","journal-title":"Pharmacol. Ther."},{"key":"56855_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2022.05.002","volume":"176","author":"P Henriques","year":"2022","unstructured":"Henriques, P., Fortuna, A. & Doktorovov\u00e1, S. Spray dried powders for nasal delivery: Process and formulation considerations. Eur. J. Pharm. Biopharm. 176, 1\u201320 (2022).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"56855_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/pharmaceutics13030385","volume":"13","author":"M Trenkel","year":"2021","unstructured":"Trenkel, M. & Scherlie\u00df, R. Nasal powder formulations: In-vitro characterisation of the impact of powders on nasal residence time and sensory effects. Pharmaceutics 13, 385 (2021).","journal-title":"Pharmaceutics"},{"key":"56855_CR16","doi-asserted-by":"publisher","first-page":"e0221330","DOI":"10.1371\/journal.pone.0221330","volume":"14","author":"H Calmet","year":"2019","unstructured":"Calmet, H. et al. Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions. PLoS One. 14, e0221330 (2019).","journal-title":"PLoS One"},{"key":"56855_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","volume":"10","author":"S G\u00e4nger","year":"2018","unstructured":"G\u00e4nger, S. & Schindowski, K. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics 10, 116 (2018).","journal-title":"Pharmaceutics"},{"key":"56855_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/head.12472","volume":"55","author":"RK Cady","year":"2015","unstructured":"Cady, R. K. et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). Headache 55, 88\u2013100 (2015).","journal-title":"Headache"},{"key":"56855_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1034\/j.1399-6576.2002.460702.x","volume":"46","author":"O Dale","year":"2002","unstructured":"Dale, O., Hjortkjaer, R. & Kharasch, E. D. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol. Scand. 46, 759\u2013770 (2002).","journal-title":"Acta Anaesthesiol. Scand."},{"key":"56855_CR20","doi-asserted-by":"publisher","first-page":"e12934","DOI":"10.1111\/jne.12934","volume":"33","author":"M Hallschmid","year":"2021","unstructured":"Hallschmid, M. Intranasal insulin. J. Neuroendocrinol. 33, e12934 (2021).","journal-title":"J. Neuroendocrinol."},{"key":"56855_CR21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-016-0641-9","volume":"76","author":"ZT Al-Salama","year":"2016","unstructured":"Al-Salama, Z. T. & Scott, L. J. Sumatriptan nasal powder: A review in acute treatment of migraine. Drugs 76, 1477\u20131484 (2016).","journal-title":"Drugs"},{"key":"56855_CR22","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/head.13530","volume":"59","author":"JS McGinley","year":"2019","unstructured":"McGinley, J. S. et al. Evaluating mean level and within-person consistency in migraine pain intensity and migraine-related disability for AVP-825 vs oral sumatriptan: Results from the COMPASS study, a randomized trial. Headache 59, 1002\u20131013 (2019).","journal-title":"Headache"},{"key":"56855_CR23","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1186\/s12889-025-22210-8","volume":"25","author":"LS Fischer","year":"2025","unstructured":"Fischer, L. S. et al. Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis. BMC Public. Health. 25, 1135 (2025).","journal-title":"BMC Public. Health"},{"key":"56855_CR24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jaip.2025.03.019","volume":"13","author":"DM Fleischer","year":"2025","unstructured":"Fleischer, D. M. et al. Pharmacokinetics and pharmacodynamics of neffy, epinephrine nasal spray, in pediatric allergy patients. J. Allergy Clin. Immunol. Pract. 13, 1335\u20131341e1 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"56855_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/1475-2875-13-501","volume":"13","author":"A Marijon","year":"2014","unstructured":"Marijon, A. et al. Efficacy of intranasal administration of artesunate in experimental cerebral malaria. Malar. J. 13, 501 (2014).","journal-title":"Malar. J."},{"key":"56855_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12936-022-04309-0","volume":"21","author":"YI Kouakou","year":"2022","unstructured":"Kouakou, Y. I. et al. Pre-referral intranasal artesunate powder for cerebral malaria: a proof-of-concept study. Malar. J. 21, 291 (2022).","journal-title":"Malar. J."},{"key":"56855_CR27","unstructured":"ICH M10 on bioanalytical method validation. Scientific guideline | European Medicines Agency (EMA). (2019). https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline"},{"key":"56855_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1051\/parasite\/2022019","volume":"29","author":"YI Kouakou","year":"2022","unstructured":"Kouakou, Y. I. et al. Assessment of quantitative and semi-quantitative biological test methods of artesunate in vitro. Parasite 29, 18 (2022).","journal-title":"Parasite"},{"key":"56855_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1208\/s12249-022-02490-8","volume":"24","author":"JW Bezuidenhout","year":"2023","unstructured":"Bezuidenhout, J. W., Aucamp, M., Stieger, N., Liebenberg, W. & Haynes, R. K. Assessment of thermal and hydrolytic stabilities and aqueous solubility of artesunate for formulation studies. AAPS PharmSciTech. 24, 33 (2023).","journal-title":"AAPS PharmSciTech"},{"key":"56855_CR30","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/cmdc.200700064","volume":"2","author":"RK Haynes","year":"2007","unstructured":"Haynes, R. K. et al. Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. ChemMedChem 2, 1448\u20131463 (2007).","journal-title":"ChemMedChem"},{"key":"56855_CR31","first-page":"66","volume":"38","author":"RJ England","year":"2000","unstructured":"England, R. J., Anthony, R., Homer, J. J. & Martin-Hirsch, D. P. Nasal pH and saccharin clearance are unrelated in the physiologically normal nose. Rhinology 38, 66\u201367 (2000).","journal-title":"Rhinology"},{"key":"56855_CR32","doi-asserted-by":"crossref","unstructured":"Carrigy, N. & Vehring, R. Engineering stable spray-dried biologic powder for inhalation. In Pharmaceutical Inhalation Aerosol Technology, 3rd edn (CRC, 2019).","DOI":"10.1201\/9780429055201-12"},{"key":"56855_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12936-024-05085-9","volume":"23","author":"J Tarning","year":"2024","unstructured":"Tarning, J. et al. Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers. Malar. J. 23, 296 (2024).","journal-title":"Malar. J."},{"key":"56855_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbrc.2023.10.001","volume":"682","author":"L Caronia","year":"2023","unstructured":"Caronia, L., Xi, R., Margolskee, R. F. & Jiang, P. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir. Biochem. Biophys. Res. Commun. 682, 138\u2013140 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"56855_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1742-1241.2000.tb11905.x","volume":"54","author":"F Boureau","year":"2000","unstructured":"Wang, et al. Comparison of Intranasal and Injectable Glucagon Administration Among Pediatric Population Responders. Diabetes Technol Ther.11: 808-816 (2023) https:\/\/doi.org\/10.1089\/dia.2023.0290","journal-title":"Int. J. Clin. Pract."},{"key":"56855_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12887-023-04203-x","volume":"23","author":"MG Prescott","year":"2023","unstructured":"Prescott, M. G. et al. Intranasal analgesia for acute moderate to severe pain in children\u2014A systematic review and meta-analysis. BMC Pediatr. 23, 405 (2023).","journal-title":"BMC Pediatr."},{"key":"56855_CR37","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.vaccine.2018.02.037","volume":"36","author":"EP Armitage","year":"2018","unstructured":"Armitage, E. P. et al. Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia. Vaccine 36, 1772\u20131780 (2018).","journal-title":"Vaccine"},{"key":"56855_CR38","first-page":"100378","volume":"12","author":"S Murdan","year":"2023","unstructured":"Murdan, S. et al. Association between culture and the preference for, and perceptions of, 11 routes of medicine administration: A survey in 21 countries and regions. Explor. Res. Clin. Soc. Pharm. 12, 100378 (2023).","journal-title":"Explor. Res. Clin. Soc. Pharm."},{"key":"56855_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/head.14685","volume":"64","author":"RB Lipton","year":"2024","unstructured":"Lipton, R. B. et al. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults. Headache 64, 266\u2013275 (2024).","journal-title":"Headache"},{"key":"56855_CR40","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.xphs.2016.03.033","volume":"105","author":"A Rygg","year":"2016","unstructured":"Rygg, A., Hindle, M. & Longest, P. W. Linking suspension nasal spray drug deposition patterns to pharmacokinetic profiles: A proof-of-concept study using computational fluid dynamics. J. Pharm. Sci. 105, 1995\u20132004 (2016).","journal-title":"J. Pharm. Sci."},{"key":"56855_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.12688\/wellcomeopenres.14849.1","volume":"4","author":"S Birgersson","year":"2019","unstructured":"Birgersson, S. et al. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open. Res. 4, 45 (2019).","journal-title":"Wellcome Open. Res."},{"key":"56855_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12936-018-2278-5","volume":"17","author":"JP Lohy Das","year":"2018","unstructured":"Lohy Das, J. P. et al. Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar. Malar. J. 17, 126 (2018).","journal-title":"Malar. J."},{"key":"56855_CR43","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.1371\/journal.pmed.0030444","volume":"3","author":"JA Simpson","year":"2006","unstructured":"Simpson, J. A. et al. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med. 3, e444 (2006).","journal-title":"PLoS Med."},{"key":"56855_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijid.2019.08.030","volume":"89","author":"YI Kouakou","year":"2019","unstructured":"Kouakou, Y. I. et al. Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria. Int. J. Infect. Dis. 89, 30\u201344 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"56855_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/1475-2875-11-255","volume":"11","author":"RS Miller","year":"2012","unstructured":"Miller, R. S. et al. Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8\u00a0mg\/kg in healthy volunteers: phase 1b study. Malar. J. 11, 255 (2012).","journal-title":"Malar. J."},{"key":"56855_CR46","doi-asserted-by":"publisher","first-page":"5484","DOI":"10.1128\/AAC.00044-12","volume":"56","author":"D Saunders","year":"2012","unstructured":"Saunders, D. et al. Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob. Agents Chemother. 56, 5484\u20135493 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56855_CR47","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","volume":"376","author":"AM Dondorp","year":"2010","unstructured":"Dondorp, A. M. et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376, 1647\u20131657 (2010).","journal-title":"Lancet"},{"key":"56855_CR48","doi-asserted-by":"publisher","first-page":"e19283","DOI":"10.1371\/journal.pone.0019283","volume":"6","author":"D Bethell","year":"2011","unstructured":"Bethell, D. et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One. 6, e19283 (2011).","journal-title":"PLoS One"},{"key":"56855_CR49","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2165\/00003495-199652060-00004","volume":"52","author":"PJ de Vries","year":"1996","unstructured":"de Vries, P. J. & Dien, T. K. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 52, 818\u2013836 (1996).","journal-title":"Drugs"},{"key":"56855_CR50","doi-asserted-by":"publisher","first-page":"e1004312","DOI":"10.1371\/journal.pmed.1004312","volume":"20","author":"JA Watson","year":"2023","unstructured":"Watson, J. A., Peto, T. J. & White, N. J. Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria. PLoS Med. 20, e1004312 (2023).","journal-title":"PLoS Med."},{"key":"56855_CR51","doi-asserted-by":"publisher","first-page":"e00060","DOI":"10.1128\/AAC.00060-19","volume":"63","author":"B Hanboonkunupakarn","year":"2019","unstructured":"Hanboonkunupakarn, B. et al. Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults. Antimicrob. Agents Chemother. 63, e00060\u2013e00019 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56855_CR52","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.297.21.2381","volume":"297","author":"HA Karunajeewa","year":"2007","unstructured":"Karunajeewa, H. A., Manning, L., Mueller, I., Ilett, K. F. & Davis, T. M. E. Rectal administration of artemisinin derivatives for the treatment of malaria. JAMA 297, 2381\u20132390 (2007).","journal-title":"JAMA"},{"key":"56855_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cts.12582","volume":"12","author":"J Shen","year":"2019","unstructured":"Shen, J. et al. Design and conduct considerations for first-in\u2010human trials. Clin. Transl. Sci. 12, 6\u201319 (2019).","journal-title":"Clin. Transl. Sci."},{"key":"56855_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jchromb.2008.10.018","volume":"876","author":"W Hanpithakpong","year":"2008","unstructured":"Hanpithakpong, W. et al. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 876, 61\u201368 (2008).","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"56855_CR55","doi-asserted-by":"crossref","unstructured":"Vass, C. M. & Payne, K. Using discrete choice experiments to inform the benefit-risk assessment of medicines: Are we ready yet? Pharmacoeconomics 35, 859\u2013866 (2017).","DOI":"10.1007\/s40273-017-0518-0"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56855-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:03:25Z","timestamp":1791371005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56855-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56855"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56855-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SP and ALB are shareholders of Eunovis. Eunovis provided a financial support for the preparation of investigational medicinal product.None of the other authors has a competing interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance: The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), and in accordance with the law n\u00b009\u2013059 of December 28th, 2009, regulating biomedical research on human in Mali. Ethical clearance was obtained from the Ethics comittee of Universit\u00e9 des Sciences, des Techniques et des Technologies de Bamako ( USTTB), Faculty of medicine and odonto-stomatology, Point G Bamako 1805 Mali, Approval date: 24\/04\/2024. The study is registered with Pan-African Clinical Trial Registry (PACTR202408719575384).","order":2,"name":"Ethics","label":"Ethics declarations","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31183"}}